The DOI matches its Crossref record.
The use of testosterone propionate in the treatment of advanced carcinoma of the breast.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many studies subsequently confirmed the beneficial effects of androgens on breast cancer (165, 167-174, 251, 252).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [251]
Citations
Cited by
Sorted by citations
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544
The Regulation of Steroid Action by Sulfation and Desulfation
Mueller, J. W., Gilligan, L. C., Idkowiak, J., Arlt, W., & Foster, P. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1036 · Cited by 419
Inhibition of human mammary and prostatic cancers by adrenalectomy.
Huggins, C., & Bergenstal, D. M. (1952) · PubMed · Cited by 325
Advances in Chemotherapy of Cancer in Man
Farber, S., Toch, R., Sears, E. M., & Pinkel, D. (1956) · Advances in cancer research · doi:10.1016/s0065-230x(08)60721-6 · Cited by 194
Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens
Cappelletti, M., & Wallen, K. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.11.003 · Cited by 181
Androgen receptor signaling pathways as a target for breast cancer treatment
Pietri, E., Conteduca, V., Andreis, D., Massa, I., Melegari, E., Sarti, S., Cecconetto, L., Schirone, A., Bravaccini, S., Serra, P., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0190 · Cited by 101
Consideration of breast cancer subtype in targeting the androgen receptor
Venema, C. M., Bense, R. D., Steenbruggen, T. G., Nienhuis, H. H., Qiu, S.-Q., van Kruchten, M., Brown, M. A., Tamimi, R. M., Hospers, G. A. P., Schroder, C. P., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.005 · Cited by 94
Androgen receptor as a targeted therapy for breast cancer.
Garay, J. P., & Park, B. H. (2012) · Europe PMC (PubMed Central) · Cited by 90
Neoplasia and Internal Environment
Bielschowsky, F. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.7 · Cited by 89
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Proverbs-Singh, T. A., Feldman, J. L., Morris, M. J., Autio, K. A., & Traina, T. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0543 · Cited by 90
“Before the 1970s, BCa was treated with DHT, testosterone, and fluoxymesterone with some clinical efficacy (Adair & Herrmann 1946, Kennedy 1958, McNamara et al. 2014).”
MethodFemale Hypoactive Sexual Desire Disorder: History and Current Status
Segraves, R. T., & Woodard, T. L. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00246.x · Cited by 82
An androgen-dependent tumor derived from a hormone- independent spontaneous tumor of a female mouse
Minesita, T., & Yamaguchi, K. (1964) · Steroids · doi:10.1016/0039-128x(64)90135-7 · Cited by 77
The development of endocrine therapy for women with breast cancer
Sainsbury, R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.006 · Cited by 79
“Following early trials with tamoxifen as a palliative treatment for metastatic breast cancer (MBC),11,14–17 improved tolerability over diethylstilboestrol or fluoxymesterone (an androgenic steroid) led to United States Food and Drug Administration (FDA) approval for the treatment of post-menopausal women with ABC.15,1…”
MethodBleach, R., & McIlroy, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00594 · Cited by 71
Li, S., Yan, X., B�langer, A., & Labrie, F. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00665681 · Cited by 70
“Many studies subsequently confirmed the beneficial effects of androgens on breast cancer [47, 48].”
BackgroundNarayanan, R., Ahn, S., Cheney, M. D., Yepuru, M., Miller, D. D., Steiner, M. S., & Dalton, J. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103202 · Cited by 70
“Until the 1970s, breast cancer was treated mostly with non-aromatizable androgens such as dihydrotestosterone or fluoxymesterone [9–11].”
BackgroundAndrogen Receptor: A Complex Therapeutic Target for Breast Cancer
Narayanan, R., & Dalton, J. T. (2016) · Cancers · doi:10.3390/cancers8120108 · Cited by 68
“Hermann and Adair, 1947, 1946 [71,84] • Treatment of patients with breast cancer with testosterone propionate showed significant regression of cancer and disappearance of metastases.”
BackgroundTHE USE OF ESTROGENS AND ANDROGENS IN ADVANCED MAMMARY CANCER
Adair, F. E. (1949) · JAMA · doi:10.1001/jama.1949.02900500001001 · Cited by 66
Self-citationBrendler, H. (1950) · Archives of Surgery · doi:10.1001/archsurg.1950.01250020438003 · Cited by 64
Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
Thakkar, A., Wang, B., Picon‐Ruiz, M., Buchwald, P., & Ince, T. A. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3807-y · Cited by 64
Venema, C. M., Mammatas, L. H., Schroder, C. P., van Kruchten, M., Apollonio, G., Glaudemans, A. W. J. M., Bongaerts, A. H. H., Hoekstra, O. S., Verheul, H. M. W., Boven, E., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193649 · Cited by 61
“Patients with metastatic breast cancer received androgens in the first half of the 20th century, with response rates of 19%–36% (3,4).”
BackgroundSutherland, A. M., Orbach, C. E., Dyk, R. B., & Bard, M. (1952) · Cancer · doi:10.1002/1097-0142(195209)5:5 · Cited by 142
Hypercalcemia in Carcinoma of the Breast
Jessiman, A. G., Emerson, K., Shah, R. C., et al. (1963) · Annals of Surgery · doi:10.1097/00000658-196303000-00009 · Cited by 56
An overview of megestrol acetate for the treatment of advanced breast cancer.
SEDLACEK, S. M. (1988) · PubMed · Cited by 55
Nathanson, I. T., & Kelley, R. M. (1952) · New England Journal of Medicine · doi:10.1056/nejm195201242460405 · Cited by 52
Sex Hormone Receptor Repertoire in Breast Cancer
Higa, G. M., & Fell, R. G. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/284036 · Cited by 52
“Moreover, therapeutic application of androgens predated the selective estrogen receptor modulators in postmenopausal women with breast cancer [72, 73].”
BackgroundPalmieri, C., Linden, H. M., Birrell, S. N., Wheelwright, S. J., Lim, E., Schwartzberg, L. S., Dwyer, A. R., Hickey, T. E., Rugo, H. S., Cobb, P. W., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00004-4 · Cited by 50
Hypercalcemia in osteolytic metastatic cancer of the breast
SWYER, A. J., Berger, J. S., Gordon, H. M., et al. (1950) · The American Journal of Medicine · doi:10.1016/0002-9343(50)90096-9 · Cited by 48
Ingle, J. N., Suman, V. J., Mailliard, J. A., Kugler, J. W., Krook, J. E., Michalak, J. C., Pisansky, T. M., Wold, L. E., Donohue, J. H., Goetz, M. P., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9152-1 · Cited by 46
“In 1958, Kennedy [6] concluded that fluoxymesterone was the androgen of choice on the basis of its oral formulation and less masculinizing effects compared to those previously reported with testosterone proprionate [ 7 ].”
ResultTraish, A. M., Feeley, R. J., & Guay, A. T. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01121.x · Cited by 41
Ponnusamy, S., Asemota, S., Schwartzberg, L. S., Guestini, F., McNamara, K. M., Pierobon, M., Font‐Tello, A., Qiu, X., Xie, Y., Rao, P. K., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.038 · Cited by 44
“(E) AR agonist DHT inhibits growth of HCI-13 PDX. HCI-13 PDX was performed as indicated above.”
BackgroundInfluentialHaagensen, C. D. (1948) · JAMA · doi:10.1001/jama.1948.62900040016005 · Cited by 41
Dehydroepiandrosterone, androgens and the mammary gland
Labrie, F. (2006) · Gynecological Endocrinology · doi:10.1080/09513590600624440 · Cited by 39
“The efficacy of androgens was thus established [58,59].”
BackgroundCarter, A. C., Cohen, E. J., & Shorr, E. (1947) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60814-6 · Cited by 39
Abnormalities in calcium metabolism in malignancy; effects of hormone therapy
Baker, W. H. (1956) · The American Journal of Medicine · doi:10.1016/0002-9343(56)90087-0 · Cited by 39
Pushing estrogen receptor around in breast cancer
Lim, E., Tarulli, G. A., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0427 · Cited by 40
“…by the clinical efficacy of androgen therapies such as methyl-testosterone and fluoxymesterone in the treatment of metastatic breast cancer, where disease regression was reported in up to 30% of cases (Adair & Herrmann 1946, Kennedy 1958, Goldenberg & Hayes 1961, Goldenberg 1964, Manni et al.”
BackgroundRevisiting Androgen Receptor Signaling in Breast Cancer
Dai, C. S., & Ellisen, L. W. (2023) · The Oncologist · doi:10.1093/oncolo/oyad049 · Cited by 38
Treatment of breast cancer through the ages
Robinson, J. O. (1986) · The American Journal of Surgery · doi:10.1016/0002-9610(86)90461-7 · Cited by 36
Emerson, W. J., Kennedy, B. J., Graham, J. N., et al. (1953) · Cancer · doi:10.1002/1097-0142(195307)6:4 · Cited by 36
THE INFLUENCE OF ANDROGENS ON SEXUALITY IN WOMEN
Foss, G. L. (1951) · The Lancet · doi:10.1016/s0140-6736(51)92408-7 · Cited by 35
Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer
Coss, C. C., Jones, A. J., & Dalton, J. T. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.010 · Cited by 34
Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts
Matthews, S. B., & Sartorius, C. A. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0275-0 · Cited by 31
METABOLIC EFFECTS OF 17-ETHYL-19-NORTESTOSTERONE IN MAN*
Spencer, H., BERGER, E., Charles, M. L., et al. (1957) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-17-8-975 · Cited by 31
Ingle, J. N., Twito, D. I., Schaid, D. J., et al. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.5.825 · Cited by 29
Huggins, C. (1952) · The Journal of Urology · doi:10.1016/s0022-5347(17)68297-1 · Cited by 29
Coss, C. C., Jones, A. J., & Dalton, J. T. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0353-8 · Cited by 29
Karnofsky, D. A., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948) · Cancer · doi:10.1002/1097-0142(194811)1:4 · Cited by 2,238
Chemotherapy of malignant disease
Gellhorn, A., & Jones, L. O. (1949) · The American Journal of Medicine · doi:10.1016/0002-9343(49)90017-0 · Cited by 28
Chemotherapy of Neoplastic Disease
Karnofsky, D. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194808192390805 · Cited by 27
EFFECT OF ESTROGENIC HORMONE ON ADVANCED CARCINOMA OF THE FEMALE BREAST
HERRMANN, J. B. (1947) · Archives of Surgery · doi:10.1001/archsurg.1947.01230070004001 · Cited by 25
Self-citationJahan, N., Jones, C., & Rahman, R. L. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111324 · Cited by 25
The current status of aromatase inhibitors in the management of breast cancer
Baum, M., & Buzdar, A. U. (2003) · Surgical Clinics of North America · doi:10.1016/s0039-6109(03)00031-8 · Cited by 23
ENDOCRINE SUBSTANCES IN THE TREATMENT OF CANCERS
Huggins, C. (1949) · JAMA · doi:10.1001/jama.1949.02910110002002 · Cited by 23
NOBLE, R. L. (1964) · Elsevier eBooks · doi:10.1016/b978-0-12-395716-0.50013-9 · Cited by 23
Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer.
Mayayo-Peralta, I., Preković, S., & Zwart, W. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100939 · Cited by 16
The use of androgens in the treatment of neoplastic disease
Segaloff, A. (1977) · Pharmacology & Therapeutics Part C Clinical Pharmacology and Therapeutics · doi:10.1016/s0362-5486(77)80010-1 · Cited by 20
Labrie, F., Li, S., B�langer, A., C�t�, J., M�rand, Y., & Lepage, M. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665803 · Cited by 18
“Many studies subsequently confirmed the beneficial effect of androgens on breast cancer [52-54].”
BackgroundChanging Concepts in the Surgery of Cancer
Dunphy, J. E. (1953) · New England Journal of Medicine · doi:10.1056/nejm195307022490105 · Cited by 18
Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules
Miller, E. C., & MILLER, J. A. (1981) · Cancer · doi:10.1002/1097-0142(19810515)47:10 · Cited by 730
Hormonal Alteration of Advanced Cancer of the Breast
Nathanson, I. T. (1947) · Surgical Clinics of North America · doi:10.1016/s0039-6109(16)32241-1 · Cited by 17
Heuson, J.-C. (1974) · Springer eBooks · doi:10.1007/978-94-011-7152-6_6 · Cited by 17
A Study of Blood Volume and Anemia in Cancer Patients
Bateman, J. C. (1951) · Blood · doi:10.1182/blood.v6.7.639.639 · Cited by 17
HERRMANN, J. B., Adair, F. E., & WOODARD, H. Q. (1947) · PubMed · Cited by 17
Self-citationKono, M., Fujii, T., Lyons, G. R., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3986-6 · Cited by 16
Endocrine Aspects of Human Cancer
Nathanson, I. T. (1946) · Elsevier eBooks · doi:10.1016/b978-1-4831-9840-8.50013-2 · Cited by 16
A critical evaluation of the current status of clinical cancer chemotherapy.
Gellhorn, A. (1953) · PubMed · Cited by 15
Li, S., Lepage, M., Mérand, Y., Bélanger, A., & Labrie, F. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961245 · Cited by 14
“Many studies subsequently confirmed the beneficial effect of androgens on breast cancer [ 35 , 36].”
TREATMENT OF ADVANCED MAMMARY CANCER WITH TESTOSTERONE
Cutler, M. (1948) · JAMA · doi:10.1001/jama.1948.02900030019004 · Cited by 14
PALLIATIVE TREATMENT OF THE PATIENT WITH ADVANCED CANCER
Daland, E. M. (1948) · JAMA · doi:10.1001/jama.1948.72890230001007 · Cited by 13
TREATMENT OF CARCINOMA OF THE HUMAN BREAST WITH TESTOSTERONE PROPIONATE:1A REPORT OF FIVE CASES
SGHWANDER, H., & Marvin, H. N. (1947) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-7-6-423 · Cited by 13
Testosterone in the Treatment of Breast Carcinoma*
Adair, F. E. (1948) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)35727-3 · Cited by 12
Self-citationHormone-treated primary operable breast carcinoma.A pathological study of thirty-three cases
Godwin, J. T., & Escher, G. C. (1951) · Cancer · doi:10.1002/1097-0142(195101)4:1 · Cited by 12
Androgen receptor agonists as breast cancer therapeutics
Caswell-Jin, J. L., & Curtis, C. N. (2021) · Nature Medicine · doi:10.1038/s41591-021-01242-8 · Cited by 11
Le Modificazioni Indotte Dal Testosterone Sulla Glicolisi Aerobia Dei Tumori
Caputo, A. (1952) · Tumori Journal · doi:10.1177/030089165203800503 · Cited by 11
Endocrine Therapy of Breast Cancer
Manni, A. (1989) · Springer eBooks · doi:10.1007/978-94-009-2536-6_20 · Cited by 11
Blackburn, C. M., & Childs, D. S. (1959) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(26)01978-6 · Cited by 11
Nuclear Receptors: From Structure to the Clinic
McEwan, I. J., & Kumar, R. (2015) · Springer eBooks · doi:10.1007/978-3-319-18729-7 · Cited by 10
Duran‐Reynals, F. (1956) · PubMed · Cited by 10
THE RATIONALE AND CLINICAL USE OF STEROID HORMONES IN CANCER
Griboff, S. I. (1952) · Archives of Internal Medicine · doi:10.1001/archinte.1952.00240050126010 · Cited by 10
Menopausal hormone therapy for breast cancer patients: what is the current evidence?
Glynne, S., Simon, J. A., Branson, A., Payne, S. J., Newson, L. R., Manyonda, I., Cleator, S. J., Douek, M., USISKIN, S. I., Tobias, J. S., et al. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002627 · Cited by 12
Renal failure during acute hypercalcaemia in patients with metastasized mammary carcinoma
Gerbrandy, J., & Hellendoorn, H. B. A. (1958) · Clinica Chimica Acta · doi:10.1016/0009-8981(58)90035-4 · Cited by 9
Hormonal treatment of metastatic carcinoma of the breast
Baker, W. H., Kelley, R. M., & Sohier, W. D. (1960) · The American Journal of Surgery · doi:10.1016/0002-9610(60)90148-3 · Cited by 9
RECENT ADVANCES IN TREATMENT OF CANCER
Rhoads, C. P. (1948) · JAMA · doi:10.1001/jama.1948.02890220015004 · Cited by 9
Huggins, C. (1947) · PubMed · Cited by 8
PALLIATIVE HORMONE THERAPY OF ADVANCED MAMMARY CANCER
Foss, G. L. (1956) · The Lancet · doi:10.1016/s0140-6736(56)90689-4 · Cited by 8
Randall, H. T. (1954) · PubMed · Cited by 8
TESTOSTERONE PROPIONATE IN TREATMENT OF RECURRENT CANCER OF THE BREAST
McGraw, A. B. (1948) · Archives of Surgery · doi:10.1001/archsurg.1948.01240020391009 · Cited by 7
Labrie, F., Simard, J., Poulin, R., Hatton, A.-C., Labrie, C., Dauvois, S., Zhao, H., PETITCLERC, L., Couët, J., Dumont, M., et al. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17805.x · Cited by 7
Testosterone Propionate in the Treatment of Breast Cancer
Kaae, S. (1949) · Acta Radiologica · doi:10.3109/00016924909176944 · Cited by 6
Ergebnisse der Radikaloperation des Mammacarcinoms
Bruck, H. G., & Lorbek, W. (1954) · Langenbeck s Archives of Surgery · doi:10.1007/bf01439353 · Cited by 6
Pyrah, L. N. (1956) · British journal of surgery · doi:10.1002/bjs.18004418311 · Cited by 5
The Sex Hormones in Advanced Breast Cancer
Lewison, E. F., & Chambers, R. G. (1952) · New England Journal of Medicine · doi:10.1056/nejm195201032460101 · Cited by 4
Cytostatische Substanzen und ihre Wirkung
Lettré, H. (1954) · Springer eBooks · doi:10.1007/978-3-642-49890-9_7 · Cited by 4
TREATMENT OF FAR ADVANCED CARCINOMA OF THE BREAST
King, W. G. (1950) · A M A Archives of Surgery · doi:10.1001/archsurg.1950.01250020636004 · Cited by 4
INDICATIO[ill] FOR THERAPEUTIC ABORTION FROM THE POINT OF VIEW OF THE SURGEON
Harvey, S. C. (1948) · JAMA · doi:10.1001/jama.1948.02890380001001 · Cited by 4
The Management of Metastatic Breast Cancer
Dobson, L. (1962) · Surgical Clinics of North America · doi:10.1016/s0039-6109(16)36728-7 · Cited by 4
Nathanson, I. T. (1950) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)35370-6 · Cited by 4
Classification of Breast Cancer Through the Perspective of Cell Identity Models
Iggo, R. D., & MacGrogan, G. M. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_11 · Cited by 3
The palliative care of inoperable and incurable recrudescent neoplasms
Copeland, M. M. (1956) · Journal of Chronic Diseases · doi:10.1016/0021-9681(56)90020-0 · Cited by 3
Davis, S. R. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.024 · Cited by 2
Metadata
- Authors
- Adair, F. E., & Herrmann, J. B.
- Venue
- Annals of Surgery
- Published
- 1946-06
- Volume
- 123
- Issue
- 6
- Pages
- 1023-1035
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2065740173
- Cited by
- 127
- References
- 0
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 1 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 9 · 2015: 5 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 15.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Male Breast Health Studies
- Keywords
- testosterone propionate, breast cancer, advanced breast cancer, androgen therapy, hormone therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review